Treatment Interruption Among Drug-Susceptible Pulmonary Tuberculosis Patients in Southern Ethiopia

References

• World Health Organization: Tuberculosis surveillance and monitoring in Europe 2019: 2017 data. 2019.
   Google Scholar
• Sachdeva KS, Kumar A, Dewan P, Kumar A, Satyanarayana S. New vision for Revised National Tuberculosis Control Programme (RNTCP): universal access-“reaching the un-reached”. Indian J Med Res. 2012;135(5):690.
   PubMed Web of Science ®Google Scholar
• Wanyonyi AW, Wanjala PM, Githuku J, Oyugi E, Kutima H. Factors associated with interruption of tuberculosis treatment among patients in Nandi County, Kenya 2015. Pan Afr Med J. 2017;28(Suppl 1). doi:10.11604/pamj.supp.2017.28.1.9347
   Google Scholar
• Mzembe T. Prevalence of Mycobacterium tuberculosis infection among adolescents in rural KwaZulu-Natal, South Africa. LSHTM. 2020.
   Google Scholar
• Genet C, Andualem T, Melese A, Mulu W, Mekonnen F, Abera B. Quality of care for tuberculosis patients in public health facilities of Debre Tabor town, Northwest Ethiopia. PLoS One. 2020;15(6):e0234988. doi:10.1371/journal.pone.0234988
   Web of Science ®Google Scholar
• Weil D, Marinkovic K, Kasaeva T. Back to the future, again: greater leadership, collaboration and accountability to accelerate progress to end TB. BMC Med. 2018;16(1):1–4. doi:10.1186/s12916-018-1165-9
   Web of Science ®Google Scholar
• FMOH. National comprehensive TB and TB/HIV training manual health care workrs. 2016: 47–48. Available from: https://www.slideshare.net/suleymanfantahun/new-ethiopian-tb-guildline-november-2016. Accessed April 28, 2021.
   Google Scholar
• Hirpa S, Medhin G, Girma B, et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. BMC Public Health. 2013;13(1):782. doi:10.1186/1471-2458-13-782
   Web of Science ®Google Scholar
• Gobena D, Ameya G, Haile K, Abreha G, Worku Y, Debela T. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study. Ann Clin Microbiol Antimicrob. 2018;17(1):30. doi:10.1186/s12941-018-0283-8
   Web of Science ®Google Scholar
• Wanyonyi AW: Factors associated with interruption of tuberculosis treatment among patients in Nandi county, Kenya (unpublished). COHES-JKUAT; 2018.
   Google Scholar
• Adane AA, Alene KA, Koye DN, Zeleke BM. Non-adherence to anti-tuberculosis treatment and determinant factors among patients with tuberculosis in northwest Ethiopia. PLoS One. 2013;8(11):e78791. doi:10.1371/journal.pone.0078791
   Web of Science ®Google Scholar
• Jakubowiak W, Bogorodskaya E, Borisov S, Danilova I. Treatment interruptions and duration associated with default among new patients with tuberculosis in six regions of Russia. Int J Infect Dis. 2008;13(3):362–368. doi:10.1016/j.ijid.2008.07.015
   Web of Science ®Google Scholar
• Lm I, Is H. Factors associated with interruption of treatment among pulmonary tuberculosis. Pan Afr Med J. 2014;17(78).
   Google Scholar
• Adejumo OA, Daniel OJ, Otesanya AF, Ashipa T, Adejumo EN, Abdur-Razzaq HA. Factors affecting treatment interruption among tb patients in lagos nigeria: isthere any need for treatment supporters? Int J Clin Med. 2016;07(06):389–398. doi:10.4236/ijcm.2016.76042
   Google Scholar
• World Health Organisation. Global tuberculosis report.Geneva: World Health Organiztion; 2018. Available from: www.who.int/tb/data. Accessed April 28, 2021.
   Google Scholar
• Desissa F, Workineh T, Beyene T. Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia. BMC Public Health. 2018;18(1):422. doi:10.1186/s12889-018-5371-3
   Web of Science ®Google Scholar
• Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study. Infect Drug Resist. 2017;10:91. doi:10.2147/IDR.S126274
   PubMed Web of Science ®Google Scholar
• Tesfay K, Tesfay S, Nigus E, Gebreyesus A, Gebreegziabiher D, Adane K. More than half of presumptive multidrug-resistant cases referred to a tuberculosis referral laboratory in the Tigray region of Ethiopia are multidrug resistant. Int J Mycobacteriol. 2016;5(3):324–327. doi:10.1016/j.ijmyco.2016.07.007
   Google Scholar
• Mulu W, Mekkonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State. Afr Health Sci. 2015;15(2):368–377. doi:10.4314/ahs.v15i2.9
   PubMed Web of Science ®Google Scholar
• Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study. BMC Public Health. 2011;11(1):696. doi:10.1186/1471-2458-11-696
   Web of Science ®Google Scholar
• Breen RA, Miller RF, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61(9):791–794. doi:10.1136/thx.2006.058867
   PubMed Web of Science ®Google Scholar
• Finlay A, Lancaster J, Holtz TH, Weyer K, Miranda A, van der Walt M. Patient-and provider-level risk factors associated with default from tuberculosis treatment, South Africa, 2002: a case-control study. BMC Public Health. 2012;12(1):56. doi:10.1186/1471-2458-12-56
   Web of Science ®Google Scholar
• Ibrahim LM, Hadejia IS, Nguku P, et al. Factors associated with interruption of treatment among pulmonary tuberculosis patients in Plateau State, Nigeria. 2011. Pan Afr Med J. 2014;17:78. doi:10.11604/pamj.2014.17.78.3464
   Google Scholar